European Society for Medical Oncology (ESMO) Sarcoma and Gastrointestinal Stromal Tumor (GIST) Symposium 2018
Milan Marriott Hotel #Milano, ITALY
ESMO’s Sarcoma & GIST Symposium is a niche meeting which attracts the most brilliant medical minds working on these disease types today. The Symposium is known as an excellent place for international networking and collaboration, featuring discussions with the key opinion leaders in these rare sub-entities.
The aim of the Symposium is to bring the translational researchers and clinicians together in an integrated approach for better patient outcome.
ESMO invites you to join us in Milan!
ESMO Preceptorship course
Prior to the Sarcoma & GIST Symposium, ESMO will run a one-day course, 5 February, led by an expert faculty, designed to provide young oncologists with a brief outline of both STS & GIST. This course could be a first contact with these diseases for oncologists who are interested in knowing more and need an introduction prior to attending the higher-level conference in the two days following.
ESMO Advanced Sarcoma course
Also prior to the Sarcoma & GIST Symposium, ESMO will run an Advanced Sarcoma Course. This is a one-day event offering an intensive discussion of a set of clinical cases of STS & GIST for professionals who are already familiar with these diseases. Attendees will benefit from discussions about challenging clinical cases with specialists from both the EU and U.S.A., leveraging the different perspectives and expertise across continents. This course is the ideal preparation for clinicians joining the Sarcoma & GIST Symposium, 5-7 February.
The ESMO Secretariat must receive one completed registration per participant and the corresponding payment in Euro by the given deadlines. Please note that Registration per day is neither possible through the pre-registration procedure nor on-site.
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
via Washington, 66
Milan, 20146 Italy
Contact No.: +41 (0)91 973 19 47
Lilly Oncology Logo
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit
Pfizer Oncology is committed to pursuing innovative treatments that are helping to redefine life with cancer. As an oncology leader with one of the most robust oncology pipelines in the industry, we are focused on translating scientific breakthroughs into clinical application. Additionally, we are dedicated to working collaboratively with the community to make a positive impact on people’s lives.
Bayer logo 2017
Bayer is committed to delivering Science For A Better Life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer currently includes four oncology products in eight indications. Several other compounds are in various stages of clinical development, with the focus on potential first-in-class approaches across the areas of novel oncogenic signaling in combination with an effective biomarker strategy, antibody drug conjugates including a thorium platform and immuno-oncology.
PharmaMar is a global biopharmaceutical company, focused on oncology and committed to research and development. PharmaMar’s Yondelis® was the first antitumor drug of marine origin to be approved for commercialization, specifically to treat soft tissue sarcoma. It has obtained approval for treating ovarian cancer in the European Union. It is available in the main oncology markets: the US, Europe and Japan.
Premium Educational Grant Supporter
Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. We base our approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell.
Contact No.: +41 (0)91 973 19 47